Federal grants to Viewpoint Molecular Targeting, Inc.
Viewpoint Molecular Targeting, Inc. in Coralville, Iowa received $6.3 million in federal grants from fiscal 2021 to 2025, across 5 awards. Its largest program was Cancer Treatment Research, with $6.3 million. It had no new grant money in fiscal 2025.
From USAspending.gov award records, updated October 31, 2026.
- Grants, FY 2021 to 2025$6.3 million
- Awards5
- Awarded in FY 2025$0
- Largest award$2.0 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 2 | $2.0 million |
| FY 2022 | 2 | $2.0 million |
| FY 2023 | 2 | $1.9 million |
| FY 2024 | 1 | $391,553 |
| FY 2025 | 0 | $0 |
Programs that fund Viewpoint Molecular Targeting, Inc.
| Program | Awards | Amount |
|---|---|---|
| Cancer Treatment Research | 5 | $6.3 million |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 5 | $6.3 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Image-guided dosimetry-based alpha particle therapy for neuroblastoma. - significance: neuroblastoma is the most common pediatric cancer, accounting for 15% of cancer deaths, with a 5-YR survival of <40% due to resistant metastases. Neuroblastoma tumors almost universally express the somatostatin re | Cancer Treatment Research | August 4, 2022 | $2.0 million |
| Combining receptor-targeted alpha particle therapy and immunotherapy to achieve complete responses in metastatic melanoma - revised. Metastatic melanoma is a lethal disease because low response rates (near 50%), acquired resistance, and severe adverse side effects limit long-term quality of life for | Cancer Treatment Research | June 29, 2022 | $1.9 million |
| Gmp peptide manufacturing, pharmacology/toxicology, and scaled radionuclide production and validation for PB-212 receptor targeted alpha-particle therapy clinical trials for metastatic melanoma. | Cancer Treatment Research | February 19, 2021 | $999,883 |
| Preclinical pharmacology, toxicology, biodistribution and dosimetry, and radionuclide production cmc validation for PB-212 receptor targeted alpha-particle therapy for neuroendocrine tumors. | Cancer Treatment Research | January 28, 2021 | $998,648 |
| Antibody-based prertargeted alpha particle therapy for ovarian cancer - project summary high-grade serous ovarian carcinomas (HGSOC) account for 75% of ovarian cancer diagnoses, and about 80% of patients have metastatic disease upon diagnosis. Metastatic hgsoc is typically treated by radical surgica | Cancer Treatment Research | June 5, 2024 | $391,553 |
Questions people ask
How much federal grant money does Viewpoint Molecular Targeting, Inc. get?
$6.3 million in 5 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Viewpoint Molecular Targeting, Inc. the most?
The Department of Health and Human Services, with $6.3 million in 5 awards.
What is Viewpoint Molecular Targeting, Inc.'s largest federal grant?
$2.0 million under Cancer Treatment Research, with its first action in the period on August 4, 2022. That counts only the money obligated in fiscal 2021 to 2025.
Other grant recipients in Coralville
Largest federal grant recipients in Iowa · Federal grants in Iowa